Richard A. Kayne - 31 Oct 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
10%+ Owner
Signature
/s/ Richard A. Kayne
Issuer symbol
N/A
Transactions as of
31 Oct 2023
Net transactions value
+$72,815
Form type
4
Filing time
02 Nov 2023, 21:21:30 UTC
Previous filing
30 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EIGR Common Stock Purchase $3,147 +11,987 +0.24% $0.2625 5,108,973 31 Oct 2023 See footnote. F1, F3
transaction EIGR Common Stock Purchase $3,228 +12,345 +0.24% $0.2615 5,121,318 31 Oct 2023 See footnote. F1, F3
transaction EIGR Common Stock Purchase $31,505 +130,509 +2.5% $0.2414 5,251,827 31 Oct 2023 See footnote. F2, F3
transaction EIGR Common Stock Purchase $27,970 +100,000 +1.9% $0.2797 5,351,827 01 Nov 2023 See footnote. F2, F3
transaction EIGR Common Stock Purchase $6,966 +23,398 +0.44% $0.2977 5,375,225 02 Nov 2023 See footnote. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Kayne shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Mr. Kayne and Propel General Partner act as the general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock.
F2 Mr. Kayne is the trustee and beneficiary of the Richard Kayne and Suzanne Kayne Living Trust dtd 01/14/1999, a California trust (the "Family Trust"), and the Family Trust acquired the referenced shares of Common Stock.
F3 Mr. Kayne expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.